Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928413 | 0.82 | MAPT (0.61) | SMN1; SMN2L3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL417679 | 0.79 | L3MBTL1 (0.73) | SMN1; SMN2L3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL10566015 | 0.78 | L3MBTL1 (0.58) | SMN1; SMN2L3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL3931514 | 0.77 | MMP2 (0.59) | ALDH1A1GAA | |
| SCHEMBL2371573 | 0.77 | L3MBTL1 (1.00) | SMN1; SMN2L3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL23832477 | 0.76 | RAPGEF3 (0.76) | SMN1; SMN2L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL29843576 | 0.76 | RAPGEF3 (0.76) | SMN1; SMN2L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL11073604 | 0.76 | L3MBTL1 (0.52) | SMN1; SMN2L3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL2371570 | 0.75 | L3MBTL1 (0.73) | SMN1; SMN2L3MBTL1MAPTALDH1A1KMT2A | |
| SCHEMBL14676376 | 0.74 | MAPT (0.63) | SMN1; SMN2L3MBTL1MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258847-A1 | Cholanic Acid Amides | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | claimed |
| EP-2044100-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-04-08 | — | — | EP | claimed |
| WO-2008009407-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | claimed |
| US-20090258847-A1 | Cholanic Acid Amides | NOVARTIS AG (CH) | 2009-10-15 | — | — | US | disclosed |
| EP-2044100-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008009407-A2 | SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258847-A1 | Cholanic Acid Amides | NR1H4, SLC10A1, CYP46A1 | SMN1; SMN2 4475/4885L3MBTL1 4031/4885MAPT 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.